Danette L. Daniels

Danette Daniels, Ph.D., joined Foghorn Therapeutics in February 2022 as VP of the Protein Degrader Platform. She brings more than 20 years of cancer research experience in focused areas of epigenetics, small molecules, and targeted protein degradation.

Prior to joining Foghorn, Danette was a R&D group leader of functional proteomics at Promega Corporation. There she led teams involved in both technology innovation and basic science research, managing collaborations with academic, biotech, and pharma laboratories. She was an early leader in the field of targeted protein degradation, pioneering approaches to monitor cellular kinetics of degradation and most recently, co-developing a new PROTAC modality. These efforts have significantly impacted the broader research community by advancing discovery and enabling mechanistic understanding of this new class of therapeutics.

Danette received her B.A. from Columbia University and a Ph.D. in biophysics from Yale University under the direction of Axel Brunger. She completed a postdoctoral fellowship at Stanford University, funded by the American Cancer Society, with Bill Weis and Roel Nusse. She has published 45 scientific peer-reviewed articles and, as a thought leader in the space, a frequent presenter at seminars, most notably at the New York Academy of Science, Dana Farber Cancer Institute, and St. Jude Children’s Research Hospital.